Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
Year of Publication2020
Issuing InstitutionWorld Health Organization
Recommendation
Status
Maintained
Recommended in favor
Conditional
Certainty of evidence
Very low
p-aminosalicylic acid may be included in the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) patients on longer regimens only if bedaquiline, linezolid, clofazimine or delamanid are not used or if better options to compose a regimen are not possible
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
WHO consolidated guidelines on drug-resistant tuberculosis treatment
Year2019
InstitutionWorld Health Organization
Guideline
WHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year2025
InstitutionWorld Health Organization